The serious and very rare forms of blood clots which had motivated the suspension of the AstraZeneca vaccine against Covid-19 by several European countries, were not observed in France with the vaccines of Pfizer-BioNTech and Moderna, indicates Friday March 19. ANSM Medicines Agency.
To read also: “Hello Doctor, do you have any doses left?”: These French people who are vaccinated without being given priority
"
No thrombosis of the cerebral venous sinus and no DIC (disseminated intravascular coagulation) associated with a deficiency in blood platelets have been reported to date in France with the Comirnaty vaccine
" from Pfizer-BioNTech and "
with the vaccine from Moderna
", writes the ANSM in a point on the surveillance of vaccines against Covid-19.
Conversely, vaccination with the vaccine from the AstraZeneca laboratory was suspended on Monday March 15 after a suspected risk of thrombosis.
It resumed in France on Friday, but the Haute Autorité de Santé (HAS) recommended that this vaccine be reserved for people aged 55 and over.
This restriction is explained by the fact that the majority of rare cases of thrombosis, which have a "
possible link
" with this vaccine, have affected women under the age of 55, notes the health agency.
The AstraZeneca vaccine has so far been recommended for people aged 50 and over.
Investigations are continuing and information concerning this risk of coagulation disorders will be added to the vaccine leaflet intended for healthcare professionals.
In addition, "
there is no proof of a quality problem linked to specific batches of the vaccine or to particular manufacturing sites
", continues the ANSM.
The European Medicines Agency (EMA / EMA) ruled on Thursday that the AstraZeneca vaccine was "
safe and effective
", adding nevertheless "
that the possibility of a link between the vaccine and cases of disseminated intravascular coagulation (coagulation disorder) and cerebral venous thrombosis (formation of clots in veins of the brain) cannot be ruled out
”.
In France, three cases have been reported: one case of disseminated intravascular coagulation (DIC) associated with stroke in a 26-year-old woman, as well as two cases of a form of cerebral venous thrombosis without platelet deficiency blood in a 51-year-old man and a 24-year-old woman.
These last two people are "
in the process of recovery
", specifies the ANSM.
No death has been reported among these three cases, she adds.
